Academician of the Chinese Academy of Engineering
Director of Tianjin Cancer Institute
Director of National Clinical Research Center for Cancer
Member of Chinese Academy of Medical Sciences
Chairman of Senologic International Society Standing Committee
Honorary President of China Anti-Cancer Association
Chief Supervisor of China Anti-Cancer Association
Editor-in-Chief of Chinese Journal of Clinical Oncology
Editor-in-Chief of Cancer Biology & Medicine
Prof. Xishan Hao, a famous Chinese oncologist. He has served as President of Tianjin Medical University and President of Tianjin Medical University Cancer Institute & Hospital (for 2 decades), Board Director of the Union for International Cancer Control (UICC), President of China Anti-Cancer Association and Vice President of Chinese Medical Association. Furthermore, he was granted the Emeritus Professor
by the Fitchburg State University (USA), the University of Dundee (UK), and Showa University (Japan).
As a surgical oncologist, Prof. Hao has been devoted to cancer care and scientific research for more than 50 years, and has made many innovative achievements in surgical oncology, cancer immunotherapy and cancer epidemiology. His works have been awarded many National Science & Technology Progress Awards. He has successively undertaken more than 20 national key scientific research projects and published more than 500 papers. As an editor-in-chief, he has published the eight-year clinical medicine textbook Oncology, as well as five monographs including Brief Oncology and Abdominal Oncology.
Prof. Hao mainly contributed to the following several different area: he took the lead role in implementing immunotherapy in solid tumors and invented a unique comprehensive cancer treatment model in China in the mid-1980s. He also pioneered “functional interstitial jejunum surgery” in the treatment of gastric cancer, a landmark breakthrough technology in the international surgical field of digestive
tract reconstruction, which has been awarded the second prize of National Science and Technology Progress in 2001. In addition, he led the team to launch the first large-scale breast cancer screening covering 1.26 million urban and rural Chinese women (2008-2011), established a long-term follow-up female breast cancer screening cohort, and formulated the first breast cancer screening guidelines for Chinese women in 2019. At the same time, he took the lead in establishing the first breast reconstruction department in China, and this department has completed more than 3,000 breast reconstruction surgeries up to now. Furthermore, Prof. Hao has been actively promoting international education and international cooperation in scientific research for decades.